Content responsibility: Op. Dr. Salim Balin · Updated: 2026-10-16
Liquid facelift: an individual plan, not a single product
Liquid facelift is not the name of one standard medical product. It describes different injectable approaches to volume, support and skin quality. This guide focuses on biostimulation with poly-L-lactic acid (PLLA) and calcium hydroxylapatite (CaHA). The aim is not simply to add more volume, but to identify what each tissue needs. It does not achieve the same result as surgical lifting in marked skin excess.
What is PLLA and how does it work?
PLLA is a biostimulator containing biodegradable polymer microparticles. It aims to support collagen formation over time, contributing to volume and tissue quality in suitable tissue. Assessment is not based only on immediate fullness as with a hyaluronic acid gel. Early appearance may partly reflect preparation fluid and swelling rather than the final result. Progress is assessed over weeks and months. The exact product’s authorised purpose and current instructions matter.
What is calcium hydroxylapatite (CaHA)?
CaHA formulations may contain microspheres in a carrier gel. Some CaHA products, for example, contain microspheres in a carboxymethylcellulose gel rather than a conventional hyaluronic acid gel. Depending on formulation and preparation, initial structural support or volume may be combined with later biostimulation. Dilution changes volume and distribution characteristics. CaHA and PLLA are not interchangeable products.
How do they differ from fillers and mesotherapy?
Hyaluronic acid fillers are commonly selected for local volume and contour. With PLLA and CaHA, collagen response is an important treatment objective. These products can nevertheless be classified as fillers or injectable implants in regulatory documents; presenting them as entirely unrelated to fillers is inaccurate. Mesotherapy is an application approach rather than a molecule, with variable products and aims. Hydration-focused mesotherapy or skin boosters are not automatically equivalent to a structural biostimulatory plan.
| Feature | Hyaluronic acid filler | PLLA | CaHA | Mesotherapy / skin booster |
|---|---|---|---|---|
| Main aim | Volume and contour | Gradual collagen response and support | Support/volume and biostimulation depending on formulation | Hydration and skin quality depending on product |
| Early appearance | Volume may be visible early; distinguish swelling | Early fullness may reflect fluid/swelling | Depends on dilution | Depends on product and technique |
| Assessment | After swelling settles | Over weeks to months | Initial effect and later response | Product-specific follow-up |
| Dissolving with hyaluronidase | May be considered for HA; not a guarantee of safety | Does not directly dissolve PLLA | Does not directly dissolve CaHA | Ingredient-dependent; not all products are dissolvable |
Planning: skin, laxity and volume loss
Assessment separates skin thickness and elasticity, fat distribution, skeletal support, volume deficit and degree of laxity. An already full face should not be needlessly overfilled, and a thin depleted face requires careful volume planning. Very thin skin raises visibility and irregularity concerns. Marked depletion may call for volume support, whereas adequate volume with laxity may shift the focus to tissue quality. Severe laxity or excess skin may not respond sufficiently to injections. Skin thickness alone does not determine PLLA or CaHA selection.
Why does age matter?
Age is considered alongside collagen loss, thinning, fat changes and skeletal support. Two people of the same age may have different needs. Heavy volume addition can be unnecessary in a younger face without depletion; more product alone may not resolve advanced laxity in an older face. There is no universal ideal age or upper cut-off, but the specific product’s authorised age range matters. For example, US patient information for one CaHA product specifies adults aged 22 or older. Current local instructions govern use in Turkey.
PLLA: candidates and contraindications
Adults seeking gradual improvement in collagen-related depletion and able to attend follow-up may be assessed. PLLA product information lists ingredient allergy, severe allergy history and susceptibility to keloids or hypertrophic scars among exclusions. Treatment in an infected or inflamed area is postponed until healed. Insufficient safety data in pregnancy, breastfeeding and children means these groups are not routine aesthetic candidates. Autoimmune disease or immunosuppressive treatment require additional assessment rather than a blanket suitability decision.
CaHA: candidates and contraindications
Selected adults may be assessed for contour, volume or tissue quality. CaHA product information lists severe allergies, component hypersensitivity and bleeding disorders as contraindications. Lidocaine-containing formulations add lidocaine or amide anaesthetic allergy considerations. Active infection requires postponement. Safety evidence is limited for pregnancy, breastfeeding, autoimmune or granulomatous disease and keloid susceptibility. Product, area and medical condition are assessed together. Anticoagulant use is not identical to a bleeding disorder, and medication must not be stopped independently.
Treatment areas and conditions
Cheek, midface and jawline concerns need different plans. Safety for lips and periocular areas is not established for some products; some PLLA product instructions exclude periocular and lip vermilion injection. A facial plan cannot simply be transferred to neck or décolleté. Area-specific authorisation, local rules, tissue thickness, previous filler and surgery are reviewed. Any use outside current instructions requires separate discussion of evidence and alternatives.
Why do preparation and dilution differ?
Powder PLLA products are reconstituted as a suspension according to manufacturer instructions. Dilution or hyperdilution of CaHA for specific aims can change distribution and visible volume effect. It does not make every area suitable or remove risks. Preparation, dose, tissue plane and schedule follow current product instructions and medical assessment; no single mixture or ratio fits everyone.
Onset and duration
PLLA assessment unfolds over time as collagen response develops. CaHA’s initial effect depends on formulation and dilution, with later biostimulatory changes possible. Sessions and intervals depend on product, baseline and response. Reports of lasting effects for some products do not justify promising the same duration to everyone. Early swelling should not be presented as the final rejuvenation effect.
Risks, reversibility and follow-up
Beyond bruising, swelling, pain and asymmetry, delayed nodules, granulomatous reactions or infection may occur. Rare vascular complications can cause tissue loss, blindness or stroke. Sudden severe pain, blanching or visual change is an emergency. PLLA and CaHA cannot be directly dissolved by hyaluronidase like hyaluronic acid. Biodegradability does not mean an unwanted result can be immediately reversed. Aftercare and massage advice are product-specific, and follow-up contacts should be agreed.
Frequently asked questions
Is PLLA or CaHA better?
There is no universally superior product. Volume needs, tissue, area, timing and product instructions are considered together.
Are conventional fillers excluded?
No. Hyaluronic acid filler may be planned for a distinct volume or contour need. Different methods can serve different purposes in the same person.
Does it replace mesotherapy?
Not necessarily. Hydration, superficial quality, volume and tissue support are different aims; the product’s role must be clear.
What if my face is already full?
More volume is not always desirable. Fat, swelling and laxity are distinguished and assessed before deciding whether a suitable non-volumising aim exists.
Will more product be enough in an older face?
Not necessarily. Injections have limits in advanced laxity and excess skin; alternatives including surgery are discussed.
What if I have previous filler?
Share product, date and site. Unknown or permanent filler may require further assessment before additional treatment.
Is massage always required?
Instructions differ. PLLA aftercare should not automatically be transferred to CaHA or another filler; follow product-specific advice.
Liquid facelift cost in Istanbul, Turkey (2026): what determines the price?
Pricing for liquid facelift in Istanbul depends on the treatment area, the technique, the number of sessions needed and the findings at examination, so a fixed price is not published on this site. Up-to-date 2026 pricing is provided after your consultation; for preliminary information you can contact us by phone or WhatsApp.
Let’s discuss the option suited to you.
WhatsAppChat on WhatsAppSources and further reading
FDA · PLLA dolgu hasta bilgilendirmesi ↗Lorenc et al. · Hyperdiluted CaHA and patient selection ↗Vleggaar et al. · PLLA patient-selection consensus ↗Fitzgerald et al. · Facial ageing and collagen stimulators ↗FDA · Dermal filler safety ↗Updated: 16 October 2026 · General patient information. Individual treatment is planned in consultation.